Rev Esp Quimioter 2021;34(Suppl.1):32-34
Ceftobiprole: a clinical view
PEDRO MARÍA MARTÍNEZ PÉREZ-CRESPO, LUIS EDUARDO LÓPEZ CORTÉS
Published: 30 September 2021
Ceftobiprole is a broad-spectrum, fifth-generation cephalosporin currently approved for community-acquired and non-ventilator-associated hospital-acquired pneumonia. High bactericidal and anti-biofilm activity has been exhibited in in vitro and animal models. This, together with its synergism with other antibiotics against gram-positive bacteria, makes it an ideal candidate for treatment of complex infections, such as those associated with devices or infective endocarditis. More clinical data are needed to achieve drug positioning.
Rev Esp Quimioter 2021; 34(Suppl. 1):32-34 [Full-text PDF]